AHK-Cu

AHK-Cu is a synthetic copper tripeptide (Ala-His-Lys) complexed with copper(II), researched primarily for hair follicle stimulation, VEGF-mediated angiogenesis at the dermal papilla, and collagen production. It is the hair-focused complement to GHK-Cu (the skin-focused copper tripeptide). AHK-Cu is used in cosmetic hair products and as a research-use-only injectable compound. It is not FDA-approved for any therapeutic indication.

What is AHK-Cu and how does the hair-follicle-targeting mechanism work?

AHK-Cu is a synthetic copper-complexed tripeptide (Ala-His-Lys + Cu²⁺) proposed to act on hair follicle stem cells and the dermal papilla through VEGF (vascular endothelial growth factor) upregulation, increased microvascular blood supply, and direct hair follicle stimulation. The mechanism is mechanistically related to but distinct from GHK-Cu — the alanine substitution at position 1 confers different tissue specificity and pharmacokinetics.

Evidence level: preclinical (ex vivo human hair follicles, dermal papilla cells, VEGF); cosmetic use; no published human clinical trials

What does the research show for AHK-Cu?

No human clinical trials of AHK-Cu have been published as of August 2026; the core dataset is laboratory work on human tissue. In the one dedicated study — Pyo and colleagues, Seoul National University, Archives of Pharmacal Research 2007 — AHK-Cu at 10⁻¹²–10⁻⁹ M stimulated the elongation of cultured human hair follicles ex vivo and the proliferation of dermal papilla cells in vitro, increased VEGF production, and decreased TGF-β1 secretion, leading the authors to conclude the complex promotes human hair follicle growth in these models. Cosmetic-formulation use is marketed on this preclinical basis; no controlled study of AHK-Cu in living humans — for hair loss or anything else — has been published., and effects on hair follicle markers in cell culture and rodent models. Cosmetic hair products incorporating AHK-Cu have shown improvements in hair density and quality parameters in cosmetic-grade evaluations. Formal Phase 2/3 RCT-grade human evidence specifically for AHK-Cu (independent of broader cosmetic formulations) is limited. Peptigrity's AHK-Cu science article walks through the 2007 dataset in detail.

Source: The effect of tripeptide-copper complex on human hair growth in vitro, Pyo H.K., Yoo H.G., Won C.H., Lee S.H., Kang Y.J., Eun H.C., Cho K.H., Kim K.H., Arch Pharm Res, 2007 · Evidence level: Preclinical; cosmetic product marketing; no formal RCTs

How does AHK-Cu compare to GHK-Cu and minoxidil?

AHK-Cu is the hair-follicle-targeted copper tripeptide complement to GHK-Cu (skin regeneration), with different sequence conferring different tissue specificity. Compared to FDA-approved minoxidil for hair loss, AHK-Cu's mechanism is fundamentally different (peptide-mediated vascular/follicle effects vs. minoxidil's vasodilator/K-channel activity), and evidence stages are not comparable. Minoxidil and finasteride are the approved hair-loss drugs with human RCT evidence; AHK-Cu is a cosmetic ingredient and research compound with laboratory data only — it is not an approved hair-loss treatment anywhere (as of August 2026). For the copper-peptide hair evidence side by side, see peptides for hair growth: GHK-Cu and AHK-Cu follicle research.

What are the documented side effects of AHK-Cu?

Side effects in cosmetic and research use are generally mild — occasional injection-site reactions for injectable use, rare scalp irritation for topical use. As with GHK-Cu, the copper content raises theoretical concerns about copper accumulation with sustained high-dose use, though clinically meaningful copper toxicity has not been reported. Long-term safety at sustained research-use injectable dosing is not well-characterized.

Evidence level: Cosmetic-use safety experience; no formal safety trials; long-term unestablished

What is the regulatory status of AHK-Cu?

AHK-Cu is not FDA-approved for any therapeutic indication. It is incorporated into cosmetic hair products under cosmetic regulation in most markets. Injectable AHK-Cu is sold as a research-use-only compound by third-party laboratories. AHK-Cu has never been on the FDA's 503A bulk-substances categories or PCAC meeting schedules — the April 2026 removals and the compounding-committee activity around copper peptides concern injectable GHK-Cu, a different tripeptide (as of August 2026). Regulatory context in are peptides legal regulatory status by country.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does AHK-Cu vendor verification matter?

AHK-Cu is a niche cosmetic and research compound with variable quality control across vendors, and like GHK-Cu, the copper-complexed form is pharmacologically distinct from the free peptide — mislabeling and improper copper ratios occur. Independent HPLC, mass spectrometry, and copper content verification are essential. Guidance in how-to-test-peptides hub.

How does Peptigrity verify AHK-Cu vendors?

Peptigrity collects independent third-party Certificates of Analysis for AHK-Cu from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does AHK-Cu do?

AHK-Cu is researched for hair follicle stimulation and dermal papilla VEGF-mediated effects, with cosmetic use focused on hair density and quality. Formal RCT-grade human evidence is more limited than the preclinical and cosmetic-use bases.

Is AHK-Cu legal to purchase?

Topical AHK-Cu is widely available in cosmetic hair products. Injectable AHK-Cu is legal to purchase as a research chemical for laboratory use in most jurisdictions but is not approved for human consumption. Country breakdown in peptide legal status guide.

How does AHK-Cu compare to minoxidil?

Different mechanisms — AHK-Cu is a copper tripeptide acting through VEGF and follicle stimulation pathways; minoxidil is a vasodilator/K+ channel opener with FDA approval for hair loss. Evidence bases are not comparable; minoxidil has Phase 3 / FDA approval, AHK-Cu has preclinical and cosmetic-use evidence.

How can I verify an AHK-Cu vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation and copper content verification. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend an AHK-Cu dose?

No. AHK-Cu is not approved for human therapeutic use and Peptigrity is an independent review platform, not a medical authority. Anyone considering injectable use should consult a licensed physician.

Can AHK-Cu and GHK-Cu be used together?

Cosmetic formulations sometimes combine both copper tripeptides, and combined topical use has been incorporated into commercial products. Combined injectable research-use protocols vary; Peptigrity does not recommend specific protocols. Anyone considering combined use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. AHK-Cu is not approved by the FDA or any other regulator for human therapeutic use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.